Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tropic hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Tropic hormone. Displaying page 1 of 1.
    EudraCT Number: 2010-021128-92 Sponsor Protocol Number: CABAZ_C_05331 Start Date*: 2010-11-11
    Sponsor Name:sanofi-aventis groupe
    Full Title: MULTICENTRE, SINGLE-ARM, OPEN LABEL CLINICAL TRIAL INTENDED TO PROVIDE EARLY ACCESS TO CABAZITAXEL IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A DOCETAX...
    Medical condition: Metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DK (Completed) ES (Completed) IT (Completed) SE (Completed) FI (Completed) AT (Completed) PT (Completed) HU (Completed) IE (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2012-003835-40 Sponsor Protocol Number: RG12-024 Start Date*: 2012-12-10
    Sponsor Name:University of Birmingham
    Full Title: A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with...
    Medical condition: Metastatic Castrate Refractory Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021785-30 Sponsor Protocol Number: A4001095 Start Date*: 2011-12-07
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFE...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SE (Prematurely Ended) FI (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Prematurely Ended) NL (Completed) PT (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003087-59 Sponsor Protocol Number: EFC6193 Start Date*: 2006-11-29
    Sponsor Name:sanofi aventis recherche et developpement
    Full Title: A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone ...
    Medical condition: Hormone Refractory Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) BE (Completed) NL (Completed) SK (Completed) DK (Completed) SE (Completed) FI (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006873-33 Sponsor Protocol Number: A4001031 Start Date*: 2009-02-23
    Sponsor Name:Pfizer, S.A.
    Full Title: ENSAYO ABIERTO, MULTICÉNTRICO, DE FARMACOCINÉTICA POR ADMINISTRACIÓN DE DOSIS MÚLTIPLES Y DE SEGURIDAD Y EFICACIA DE 48 SEMANAS DE MARAVIROC EN COMBINACIÓN CON UN TRATAMIENTO DE BASE OPTIMIZADO PAR...
    Medical condition: Tratamiento VIH
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended) FR (Ongoing) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:28:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA